VA
XFOR icon

Verdad Advisers’s X4 Pharmaceuticals XFOR Stock Holding History

Verdad Advisers’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.64M Buy
+352,093
New +$1.44M 1.57% 10

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Verdad Advisers's XFOR Position: Q2 2026 in Review

Verdad Advisers opened a new position in X4 Pharmaceuticals (XFOR) in Q2 2026: 352,093 shares worth $1.64M. The stake represents 1.57% of the portfolio and ranks #10 among its holdings.

89 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.

  • Verdad Advisers held 352,093 shares of X4 Pharmaceuticals worth $1.64M as of Q2 2026.
  • X4 Pharmaceuticals was a new Verdad Advisers position in Q2 2026.
  • X4 Pharmaceuticals made up 1.57% of Verdad Advisers's portfolio in Q2 2026, its #10 holding.
  • 89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.